科研级 Spartalizumab, Anti-CD279 Recombinant Antibody, Research Grade Spartalizumab
Molecular Name
Spartalizumab
Size
1mg, 5mg
CAS Number
1935694-88-4
Isotype
IgG4 Kappa
Clonality
Monoclonal
Concentration
1mg/ml
Source
CHO Cells
Purity
≥95% as determined by SDS-PAGE
Buffer
Supplied in PBS, PH7.5
Target
PDCD1/PD1/CD279[Homo sapiens]
Background
Spartalizumab (INN, development code PDR001) is a monoclonal antibody that is being investigated for melanoma. This drug is being developed by Novartis. As of 2018, spartalizumab is undergoing Phase III trials.